Hepatocellular carcinoma in patients with HIV Journal Article


Authors: El Dika, I.; Harding, J. J.; Abou-Alfa, G. K.
Article Title: Hepatocellular carcinoma in patients with HIV
Abstract: Purpose of review: Hepatocellular carcinoma (HCC) is becoming an important cause of mortality in patients with HIV, attributed to coinfection with hepatitis C virus, hepatitis B virus, and the longer survival advantage these patients are achieving after introducing the highly active antiretroviral therapy (HAART) regimens. Recent findings: In addition to hepatitis infection, immunosuppression secondary to HIV infection, direct impact of the virus on liver parenchyma, and the use of hepatotoxic antiretroviral drugs, all contribute to HCC pathogenesis. Screening is very important in this particular population; data on population-specific guidelines are still controversial and scarce. Liver transplantation remains the treatment of choice in eligible patients. Trials on sorafenib have not included patients with HIV; yet, we know from small retrospective series that it might be safe and effective. Summary: In the HAART era, HCC is arising as a common non-AIDS defining cancer with high impact on morbidity and mortality of HIV-infected patients. Candidates for liver transplantation should be offered this option regardless of HIV infection. Safety and efficacy of sorafenib and other treatment modalities should be further studied and offered as deemed applicable to HIV patients diagnosed with HCC. Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.
Keywords: hepatocellular carcinoma; sorafenib; liver transplantation; screening; highly active antiretroviral therapy; hiv
Journal Title: Current Opinion in HIV and AIDS
Volume: 12
Issue: 1
ISSN: 1746-630X
Publisher: Wolters Kluwer Health, Inc  
Date Published: 2017-01-01
Start Page: 20
End Page: 25
Language: English
DOI: 10.1097/coh.0000000000000335
PROVIDER: scopus
PUBMED: 27755152
DOI/URL:
Notes: Review -- Export Date: 2 February 2017 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. James Joseph Harding
    250 Harding
  2. Ghassan Abou-Alfa
    568 Abou-Alfa
  3. Imane El Dika
    65 El Dika